Ultragenyx Pharmaceutical Inc. Q4 2024 Earnings Conference Call
Company Participants:
Joshua Higa – VP, IR
Emil Kakkis – CEO and President
Erik Harris – CCO
Howard Horn – CFO
Eric Crombez – CMO
Conference Call Participants:
Tazeen Ahmad – Bank of America
Salveen Richter – Goldman Sachs
Gena Wang – Barclays
Yaron Werber – TD Cowen
Joon Lee – Truist Securities
Jeff Hung – Morgan Stanley
Rick Miller – Cantor Fitzgerald
Luca Issi – RBC Capital
Liisa Bayko – Evercore ISI
Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
The conference call featured several key company executives, including CEO and President Emil Kakkis, who provided insights into the financial performance and business strategy of Ultragenyx Pharmaceutical Inc. for the fourth quarter and full year of 2024.
During the call, CFO Howard Horn discussed the company’s financial results and highlighted key milestones achieved in the past year. CMO Eric Crombez shared updates on the company’s pipeline of innovative therapies, while CCO Erik Harris outlined the commercial strategy moving forward.
Analysts from various investment banks, including Bank of America, Goldman Sachs, and Barclays, participated in the call and asked questions about the company’s financial outlook, competitive landscape, and growth prospects.
Overall, the conference call provided valuable insights into Ultragenyx’s performance and future potential, leaving investors and analysts optimistic about the company’s prospects in the biopharmaceutical industry.
How This Will Affect Me:
As an investor, the positive financial results and strategic updates shared during the conference call are likely to boost confidence in Ultragenyx Pharmaceutical Inc. This could lead to an increase in the company’s stock price, resulting in potential gains for shareholders like myself.
How This Will Affect the World:
Ultragenyx’s continued success in developing innovative therapies for rare diseases has the potential to make a significant impact on global healthcare. By providing treatments for underserved patient populations, the company is contributing to the advancement of medical science and improving the quality of life for patients worldwide.
Conclusion:
The Ultragenyx Fourth Quarter and Full Year 2024 Financial Results Conference Call provided valuable insights into the company’s performance and future prospects. With a strong pipeline of therapies and a focus on addressing unmet medical needs, Ultragenyx is poised for continued growth and success in the biopharmaceutical industry.
